“Erik is outstanding in advancing product programs forward in an expeditious manner through his leadership, passion and logic for addressing the most critical issues as timely as possible. He is also an excellent presenter, communicator and collaborator.”
Erik Karrer
San Francisco, California, United States
804 followers
500+ connections
804 followers
500+ connections
About
Biotech professional with 20 years drug discovery experience. Demonstrated leadership in…
Activity
-
We are delighted to welcome Dr. Laura Carter to our Leadership team!
We are delighted to welcome Dr. Laura Carter to our Leadership team!
Liked by Erik Karrer
-
I am thrilled to welcome Ben Glicksberg to Character Biosciences! Ben will lead our #datascience and #machinelearning. Looking forward to co-write…
I am thrilled to welcome Ben Glicksberg to Character Biosciences! Ben will lead our #datascience and #machinelearning. Looking forward to co-write…
Liked by Erik Karrer
-
An excellent review of NASH by one of my colleagues at Alacrita.
An excellent review of NASH by one of my colleagues at Alacrita.
Liked by Erik Karrer
Experience
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Education
-
University of California, Davis
-
Activities and Societies: Phi Sigma Biological Honor Society (1992)
-
-
Publications
-
A Phase 1 Dose-Escalation Study of ASP2409, a Selective T-Cell Costimulation Inhibitor, in Stable Rheumatoid Arthritis Patients on Methotrexate Therapy
Clinical Pharmacology in Drug Development
ASP2409 represents a new class of CTLA4-Ig molecules with higher binding avidity and selectivity to CD86. This first-in-human study was to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of ASP2409 in stable rheumatoid arthritis patients on methotrexate therapy with a randomized, double-blind, placebo-controlled dose-escalation study design. Patients were enrolled and randomized in each of 8 dose-escalation cohorts ranging from 0.001 to 3.0 mg/kg to receive either…
ASP2409 represents a new class of CTLA4-Ig molecules with higher binding avidity and selectivity to CD86. This first-in-human study was to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of ASP2409 in stable rheumatoid arthritis patients on methotrexate therapy with a randomized, double-blind, placebo-controlled dose-escalation study design. Patients were enrolled and randomized in each of 8 dose-escalation cohorts ranging from 0.001 to 3.0 mg/kg to receive either ASP2409 or placebo in a sequential manner. Escalation to higher dose levels occurred in the absence of dose-limiting toxicity. A total of 57 patients completed the study. ASP2409 showed nonlinear PK over the dose range of 0.01 to 3.0 mg/kg following a single intravenous administration, indicating target-mediated drug disposition. Area under the concentration-time curve (AUC) and maximum concentration (Cmax ) increased at a greater than dose-proportional rate. The half-life of ASP2409 increased dose dependently and ranged from 1.57 to 6.68 days. ASP2409 showed a dose-dependent increase in the extent and duration of CD86 receptor occupancy. There were no clinically relevant safety issues up to a single dose of 3.0 mg/kg. No maximum tolerated dose was reached. The incidence and duration of antidrug antibodies did not correlate with adverse events.
Other authors -
-
ASP2408 and ASP2409, Novel CTLA4-Ig variants with CD86-selective Ligand Binding Activity and Improved Immunosuppressive Potency, Created by Directed Evolution
Protein Engineering Design and Selection (PEDS)
The CTLA4-Ig therapeutics abatacept and belatacept inhibit CD28-mediated T cell activation by binding CD80 (B7-1) and CD86 (B7-2) co-stimulatory ligands. Both compounds preferentially bind CD80, yet CD86 has been implicated as the dominant co-stimulatory ligand. Using directed evolution methods, novel CTLA4-Ig variants were created with selective CD86 binding affinity, a property that confers increased immunosuppressive potency and potentially improved efficacy and safety profiles. Relative to…
The CTLA4-Ig therapeutics abatacept and belatacept inhibit CD28-mediated T cell activation by binding CD80 (B7-1) and CD86 (B7-2) co-stimulatory ligands. Both compounds preferentially bind CD80, yet CD86 has been implicated as the dominant co-stimulatory ligand. Using directed evolution methods, novel CTLA4-Ig variants were created with selective CD86 binding affinity, a property that confers increased immunosuppressive potency and potentially improved efficacy and safety profiles. Relative to abatacept (wild-type CTLA4-Ig), ASP2408 and ASP2409 have 83-fold and 220-fold enhanced binding affinity to CD86 while retaining 1.5-fold and 5.6-fold enhanced binding affinity to CD80, respectively. Improvements in CD86 binding affinity correlates with increased immunosuppressive potencyin vitroandin vivo Our results highlight the power of directed evolution methods to obtain non-intuitive protein engineering solutions and represent the first examples of CD86-selective CTLA4-Ig compounds that have entered clinical trials.
Other authors -
-
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of ASP2408, a Potent Selective T-Cell Costimulation Modulator After Single and Multiple Ascending Doses in Healthy Volunteers and RA Patients
Clinical Pharmacology in Drug Development
ASP2408 is a next-generation anti–cytotoxic T lymphocyte antigen-4 fusion protein engineered for improved CD86 binding affinity as a treatment for rheumatoid arthritis (RA). In 72 healthy subjects (n = 6/treatment), ASP2408 was administered as single ascending doses intravenously at 0.003 to 10.0 mg/kg or subcutaneously at 0.3 to 3.0 mg/kg. It showed decreased clearance and prolonged half-life with increasing doses, consistent with target-mediated disposition. The apparent bioavailability was…
ASP2408 is a next-generation anti–cytotoxic T lymphocyte antigen-4 fusion protein engineered for improved CD86 binding affinity as a treatment for rheumatoid arthritis (RA). In 72 healthy subjects (n = 6/treatment), ASP2408 was administered as single ascending doses intravenously at 0.003 to 10.0 mg/kg or subcutaneously at 0.3 to 3.0 mg/kg. It showed decreased clearance and prolonged half-life with increasing doses, consistent with target-mediated disposition. The apparent bioavailability was 36.3%–56.7% across single subcutaneous doses. Sixteen RA patients (n = 8/treatment) on stable methotrexate received 3 × 3.0 mg/kg subcutaneously every 4 weeks or every 2 weeks. Similar to single-dose treatment, ASP2408 concentrations peaked 2 to 3 days postdose, with a median t1/2 of approximately 8 days. Using CD86 receptor occupancy (RO) as a mechanistic biomarker, ASP2408 demonstrated dose-dependent binding to its target. ASP2408 3.0 mg/kg subcutaneously every 4 weeks and every 2 weeks led to a mean %CD86 RO ≥ 74.7% and ≥ 81.5%, respectively, within each dosing interval. ASP2408 was well tolerated across studies with no evidence of dose-limiting toxicity or clinically significant changes in clinical laboratory test results, vital signs, or 12-lead electrocardiograms. ASP2408 elicited antidrug antibodies in the majority of patients, but with no clinical sequelae.
Other authors -
-
A Pilot Trial Targeting the ICOS-ICOS-L Pathway in Nonhuman Primate Kidney Transplantation.
American Journal of Transplantation - doi: 10.1111/ajt.13100
Costimulation blockade with the B7-CD28 pathway-specific agent belatacept is now used in clinical kidney transplantation, but its efficacy remains imperfect. Numerous alternate costimulatory pathways have been proposed as targets to synergize with belatacept, one of which being the inducible costimulator (ICOS)-ICOS ligand (ICOS-L) pathway. Combined ICOS-ICOS-L and CD28-B7 blockade has been shown to prevent rejection in mice, but has not been studied in primates. We therefore tested a novel…
Costimulation blockade with the B7-CD28 pathway-specific agent belatacept is now used in clinical kidney transplantation, but its efficacy remains imperfect. Numerous alternate costimulatory pathways have been proposed as targets to synergize with belatacept, one of which being the inducible costimulator (ICOS)-ICOS ligand (ICOS-L) pathway. Combined ICOS-ICOS-L and CD28-B7 blockade has been shown to prevent rejection in mice, but has not been studied in primates. We therefore tested a novel ICOS-Ig human Fc-fusion protein in a nonhuman primate (NHP) kidney transplant model alone and in combination with belatacept. ICOS-Ig did not prolong rejection-free survival as a monotherapy or in combination with belatacept. In ICOS-Ig alone treated animals, most graft-infiltrating CD4(+) and CD8(+) T cells expressed ICOS, and ICOS(+) T cells were present in peripheral blood to a lesser degree. Adding belatacept reduced the proportion of graft-infiltrating ICOS(+) T cells and virtually eliminated their presence in peripheral blood. Graft-infiltrating T cells in belatacept-resistant rejection were primarily CD8(+) CD28(-) , but importantly, very few CD8(+) CD28(-) T cells expressed ICOS. We conclude that ICOS-Ig, alone or combined with belatacept, does not prolong renal allograft survival in NHPs. This may relate to selective loss of ICOS with CD28 loss.
Other authors -
-
Strategies to Develop Allergy Therapeutics with Applications of Directed Molecular Evolution
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents
Karrer E, Bass S, Parmley S and Punnonen J: Strategies to Develop Allergy Therapeutics with Applications of Directed Molecular Evolution. Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents 2: 228-236 (2003).
-
Display epitopes on the surface of tobacco mosaic virus: Impact of charge and isoelectric point of the epitope on virus-host interactions
J. Mol. Biol
Bendahmane M, Koo M, Karrer E and Beachy RN: Display epitopes on the surface of tobacco mosaic virus: Impact of charge and isoelectric point of the epitope on virus-host interactions. J. Mol. Biol. 290: 9-20 (1999).
-
Cloning of tobacco genes that elicit the hypersensitive response
Plant Mol. Biol.
Karrer E, Beachy R, Holt C: Cloning of tobacco genes that elicit the hypersensitive response. Plant Mol. Biol. 36: 681-690 (1998).
-
Three cis-elements required for rice alpha-amylase Amy3D expression during sugar starvation
Plant Mol. Biol.
Hwang Y-S, Karrer E, Thomas BR, Chen L and Rodriguez RL: Three cis-elements required for rice alpha-amylase Amy3D expression during sugar starvation. Plant Mol. Biol. 36: 331-341 (1998)
-
In situ isolation of mRNA from individual plant cells: Creation of cell-specific cDNA libraries
Proc. Natl. Acad. Sci.
Karrer E, Lincoln J, Hogenhout S, Bennett A, Bostock R, Martineau B, Lucas W, Gilchirst D, and Alexander D: In situ isolation of mRNA from individual plant cells: Creation of cell-specific cDNA libraries. Proc. Natl. Acad. Sci. 92: 3814-3818 (1995).
-
Metabolic regulation of rice alpha-amylase and sucrose synthase genes in planta.
The Plant Journal
Karrer E, and Rodriguez R: Metabolic regulation of rice -amylase and sucrose synthase genes in planta. The Plant J. 2: 517-523 (1992).
Patents
-
Immunosuppressive polypeptides and nucleic acids
Issued US 8,318,176
U.S. Patent # 8,318,176: Immunosuppressive polypeptides and nucleic acids - Karrer EE, Paidhungat MM, Bass SH, Neighbors M, Punnonen J and Chapin SJ. Issued November 27, 2012.
-
Immunosuppressive polypeptides and nucleic acids
Issued US 8,283,447
U.S. Patent # 8,283,447: Immunosuppressive polypeptides and nucleic acids - Karrer EE, Paidhungat MM, Bass SH, Neighbors M, Punnonen J and Chapin SJ. Issued October 9, 2012.
-
Immunosuppressive polypeptides and nucleic acids
Issued US 8,268,587
U.S. Patent # 8,268,587: Immunosuppressive polypeptides and nucleic acids - Karrer EE, Paidhungat MM, Bass SH, Neighbors M, Punnonen J and Chapin SJ. Issued Sept 18, 2012
-
Antibody diversity generation
Issued US 8,252,727
U. S. Patent # 8,252,727: Antibody diversity generation – Karrer Erik, Bass Steven H, Whalen Robert and Patten Philip A. Issued August 28, 2012
-
Immunosuppressive polypeptides and nucleic acids
Issued US 8,071,095
U. S. Patent # 8,071,095: Immunosuppressive polypeptides and nucleic acids - Karrer Erik E, Paidhungat MM, Bass SH, Neighbors M, Punnonen J and Chapin SJ. Issued December 6, 2011
-
Immunosuppressive Polypeptides and Nucleic Acids
Issued US 7,794,718
U.S. Patent # 7,794,718: Immunosuppressive Polypeptides and Nucleic Acids – Karrer EE, Paidhungat MM, Bass SH, Neighbors M, Punnonen J and Chapin SJ. Issued September 14, 2010.
-
THERAPEUTIC COMPOSITIONS AND METHODS FOR AGE-RELATED MACULAR DEGENERATION
Filed PCT/US2023/070241
Other inventors -
-
THERAPEUTIC LIPID PROCESSING COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED MACULAR DEGENERATION
Filed PCT/US2023/067012
Other inventors -
-
Polypeptide inhibitors of VLA4
Filed US 20120135912
U. S. Patent Application # 20120135912: Polypeptide inhibitors of VLA4 – Paidhungat Madan M, Nanisetti Amulya, Bouquin Thomas, Andersen Kim Vilbour, Chapin Stephen J, Krebber Claus, Fan Rong A, Malashock Daniel, Brideau-Andersen Amy, Karrer Erik, Devens Bruce, Bass Stephen H. Published May 31, 2012
-
Polypeptide inhibitors of VLA4
Filed EU EP2569331
Paidhungat Madan M, Nanisetti Amulya, Bouquin Thomas, Andersen Kim Vilbour, Chapin Stephen J, Krebber Claus, Fan Rong A, Malashock Daniel, Brideau-Andersen Amy, Karrer Erik, Devens Bruce, Bass Stephen H
-
Immunosuppressive Polypeptides and Nucleic Acids
Filed EU EP2385065
European Patent Application # EP2385065: Immunosuppressive Polypeptides and Nucleic Acids - Karrer EE, Paidhungat MM, Bass SH, Neighbors M, Punnonen J and Chapin SJ. Published November 9, 2011
-
Immunosuppressive Polypeptides and Nucleic Acids
Filed EU EP2222697
European Patent Application # EP2222697: Immunosuppressive Polypeptides and Nucleic Acids - Karrer EE, Paidhungat MM, Bass SH, Neighbors M, Punnonen J and Chapin SJ. Published September 1, 2010
Honors & Awards
-
SVP Award for Excellence
Astellas
Recognizing contributions towards the successful integration of Perseid into the global Astellas organization
-
NIH National Research Service Award for Postdoctoral Fellows
NIH
-
Letter of Distinction
UC Davis
Recognition of outstanding performance during Ph.D. qualifying examinations
Languages
-
German
-
Recommendations received
9 people have recommended Erik
Join now to viewOther similar profiles
Explore more posts
-
Amanda Haupt
"San Diago... which of course in German means..." (you can fill in the blank in your head if you know the reference 😂) But I AM in gorgeous San Diego! Please reach out if you've been curious about base editing and would like to have an in person seminar in the So Cal region this month! Why base editing for your therapeutic cell engineering pipelines? ⏲️ SAVE TIME- reduce timelines on multiplex edited cell products by up to 90% 💰 SAVE ON COSTS of manufacturing when less steps are required to reach the end product 💪 HEALTHIER CELL PRODUCTS - gene editing with our platform avoids double strand DNA breaks, reducing the risk of genomic translocations, reducing cytotoxicity, and supporting normal growth rates
1 Comment -
BioData Solutions
#Bioanalytical #drugdevelopment can be challenging. Come join us for a day of learning and sharing your concerns (or experiences) at PBSS International workshop "Current State of Bioanalysis for Biologics and Cell/Gene Therapy Products" Refining Established Approaches for New Complex Therapies" #cellandgenetherapies #biologics
-
Los Angeles Biotech Networks
Genetic Analysis Reveals Bacterium’s Survival Tactics https://lnkd.in/g_SDQumC Staphylococcus aureus is a type of bacterium that is usually harmless, but for some can cause potentially life-threatening infections. A study reveals how it can adapt and evolve to survive at a genetic level. The [...]
-
Matt DiLeo
Here’s how we can engineer plants to CREATE light, instead of just consuming it. 🌿🧬💡 💡 The first glow-in-the-dark plant was made in the 80’s by adding DNA from the firefly luciferase gene and feeding the plant luciferin (a substrate that releases light when catalyzed by luciferase in the presence of oxygen). 🪼 Since, glow-in-the-dark enzymes and other proteins (especially GFP, green fluorescent protein) have become major tools in biotechnology labs. 🔮 But could we see their crossover into Consumer Biology? Could we one day read by the light of our houseplants? Or walk down streets shaded by trees by day and illuminated by them at night? 🐟🐠 Aside from some novelties such as glow-in-the-dark aquarium pets, we haven’t seen much crossover of these technologies from reagents to home goods - mostly due to the very low light output achieved to date. But there’s been a new development…. 🍄 Researchers have engineered a more efficient luciferin:luciferase system from fungi (these systems evolved independently multiple times) into plants. They also further increased key precursors of the light-producing molecules via a combined gene silencing and over-expression approach. 🧪 We use these same approaches in molecular farming to increase the production of valuable molecules like sweeteners in engineered plants. 💡 This ambitious and comprehensive strategy to boost light output had a major impact on the light production of these newly-engineered plants! 📈 And better yet - the researchers documented that even this record light output is far below the theoretical maximum… 🚀 Meaning there’s immediate potential to increase light output even further! 🤔 Perhaps (one day not so far in the future) bright enough to read by. 📚 #molecularfarming #bioengineering #syntheticbiology #future #consumerbiology
4 Comments -
CRISPR Medicine News
𝗖𝗥𝗜𝗦𝗣𝗥𝗠𝗘𝗗𝟮𝟱: 𝗠𝗲𝗲𝘁 𝗼𝘂𝗿 𝗻𝗲𝘅𝘁 𝘀𝗶𝘅 𝗶𝗻𝘃𝗶𝘁𝗲𝗱 𝘀𝗽𝗲𝗮𝗸𝗲𝗿𝘀! We are delighted to unveil the next six renowned experts joining the speaker line-up for #CRISPRMED25. Their pioneering work spans the forefront of genome editing, protein research, biomedical engineering and precision medicine. Dana Carroll, Distinguished Professor Emeritus of Biochemistry at the University of Utah School of Medicine, is a true pioneer in the genome-editing field. His research focused on improving and pursuing applications of genome editing technology, using all of the current platforms — ZFNs, TALENs, and CRISPR-Cas. His team was the first to demonstrate that zinc finger nucleases can stimulate targeted mutagenesis and gene replacement in living systems. Kiana Aran is a Biomedical Entrepreneur and Bioengineering Professor at UC San Diego as well as co-founder and former CSO of Cardea Bio (part of Paragraf®), a biotechnology company mass-producing 2D electronics for healthcare applications. As co-founder of CRISPR QC, she paved the way for innovative analytical tools for CRISPR. Guillermo Montoya, Research Director and Group Leader at the Novo Nordisk Foundation Center for Protein Research, University of Copenhagen, investigates cellular mechanisms at the atomic level by combining X-ray crystallography and cryo-electron microscopy to uncover macromolecule structure and function in cell cycle progression and genome integrity. Alessio Strano, postdoctoral scientist in the Platt Laboratory for Biological Engineering of ETH Zürich, advances research on CRISPR- and AAV-based technologies for functional genomic screens directly 𝘪𝘯 𝘷𝘪𝘷𝘰. His current research focuses on physiological and disease processes in aging and neurodegeneration. Martin Pacesa is a postdoctoral researcher in the Laboratory of Protein Design and Immunoengineering at EPFL in Lausanne. Martin earned his Ph.D. from the Universität Zürich | University of Zurich, where he explored the structural and biochemical mechanisms of CRISPR-Cas systems. At EPFL, Martin has expanded his research into AI-based protein design and co-developed a method for the functional solubilisation of membrane proteins. Additionally, he developed BindCraft, an open-source AI pipeline for accurate 𝘥𝘦 𝘯𝘰𝘷𝘰 binder design, without the need for extensive experimental screening or optimisation. Xavier Duportet, Co-founder and CEO of Eligo Bioscience, leads the development of a cutting-edge pipeline of precision medicines to address unmet medical needs in immunoinflammation, oncology, and infectious diseases through 𝘪𝘯 𝘷𝘪𝘷𝘰 microbiome editing. See our 𝗳𝘂𝗹𝗹 𝗶𝗻𝘃𝗶𝘁𝗲𝗱 𝘀𝗽𝗲𝗮𝗸𝗲𝗿 𝗹𝗶𝘀𝘁 here: 👉 https://lnkd.in/d7svujCE We are looking forward to your registration! 👉 https://lnkd.in/d2wyXiAH #CRISPRMED25 #crisprmedicinenews #precisionmedicine
1 Comment -
Rachel Kindt Ph.D.
Curious about career options beyond the bench? Join PBSS on May 30th for a free online workshop diving into the roles, attributes and paths into Project Management and Regulatory Affairs. It's been a lot of fun putting this together with Shichang Miao, Enas Mahmoud, and Dean Wilson at PBSS International as well as the knowledgable group of PM and Regulatory professionals who have walked the walk of career transitions themselves. First in a planned series! #careergrowth #findyourpath #keeplearning
-
David Mead
Robb Stankey will be presenting a poster at next week's Natural Product Discovery and Development in the Genomic Era conference in San Diego, CA. 🌴☀️ The title of the poster is "Accelerating Natural Product Discovery & Production through Metabologenomics, BGC Cloning, & Genome Engineering"—please stop by and say hi! https://lnkd.in/ghuQXJu4 Society for Industrial Microbiology and Biotechnology Activate to view larger image,
1 Comment -
Eduardo Ceballos
Folks, xBiologix is heading to #BIO2024 to connect solid phase tumor profiling with translational research & preclinical drug development. Join us in San Diego and learn how a simplified single staining step & multiplexed immunofluorescence makes profiling the required number of biomarkers available to virtually any research scientist or pathologist. #spatialbiology #multiplexIF
-
Tezcat Biosciences
As a selected Showcase Company from the NCI SBIR Development Center's Investor Initiative, Tezcat Biosciences will be at #BIO2024 in San Diego June 3-6. Tezcat Biosciences is developing a receptor-independent drug delivery technology, initially positioned for RAS pathway activated cancers. We are seeking industry collaborations to expand our pipeline as our technology is payload and disease agnostic. If your company has an interesting, hard to deliver payload and/or works in the following disease areas, we would like to set up a time to meet at the event. #SmallMolecule #siRNA #Radiopharmaceutical #PROTAC #Immunomodulatory #EndosomeEscape #CardiovascularDisease #MASH #NASH #InflammatoryDisease #NeurodegenerativeDisease #InfectiousDisease #AnimalHealth To schedule a time to meet inside the event, please use BIO’s One-on-One Partnering™ System. Outside the event, please DM either Dr. Craig Ramirez, Ph.D. or Dr. Andrew D. Hauser to schedule a time to meet. #biotech #businessdevelopment #networking #partnering https://lnkd.in/eEDtKaAK
-
Los Angeles Biotech Networks
Genetic Analysis Reveals Bacterium’s Survival Tactics https://lnkd.in/g_SDQumC Staphylococcus aureus is a type of bacterium that is usually harmless, but for some can cause potentially life-threatening infections. A study reveals how it can adapt and evolve to survive at a genetic level. The [...] #LosAngeles #OrangeCountyCA #Biotech #Lifescience #News
-
M. Stella Ritorto
https://lnkd.in/etB2Pmqt : a new compound called TRanscriptional Activator of p53 (TRAP-1) is able to engage p53-Y220C and BRD4 in a ternary complex, which potently re-activates mutant p53, resulting in rapid upregulation of p21 and other p53 target genes and inhibits the growth of p53Y220C-expressing cell lines.
-
Eric Grumbach, MBA
An Automated High-throughput Affinity Capture Mass Spectrometry Platform with Data Independent Acquisition A recent manuscript from researchers Hui Jing, Paul Richardson, Gregory Potts, Sameera Senaweera, Violeta Marin, Ryan McClure, Adam Banlasan, Hua Tang, James Kath, Renze (Arthur) Ma, and Jon Williams from AbbVie discusses the development, optimization, and application of a streamlined #chemoproteomics workflow Key Points: - #Automation of a workflow employing biotinylated probes and streptavidin magnetic beads for small molecule target enrichment has been developed to overcome the challenge of tedious and time-consuming sample preparation by leveraging the Integra Assist Plus from INTEGRA Biosciences. - A data-independent acquisition (#DIA) MS method was developed to establish a label-free quantitative chemical proteomic kinome profiling workflow leveraging the Evosep One platform from Evosep Biosystems and #Orbitrap Exploris 480 from Thermo Fisher Scientific. - Advancements in ultra-fast and sensitive MS instrumentation yields the possibility to perform miniaturized affinity capture and increase throughput to 100 SPD or faster. The full manuscript can be read here https://lnkd.in/gX2PhDMT To learn more about the Evosep One platform, visit our website www.evosep.com or reach out to me for more information.
-
Nicolas Meier
Discover Anjarium Biosciences novel anion exchange ligand poster for purifying Lentivirus vectors (LVVs), featured at the ASGCT 2024 conference in Baltimore. When the ligand is attached to a resin matrix, it can either directly capture LVVs from clarified media or be utilized in a polishing step. Over 60% of infectious lentivirus can be reliably recovered under unprecedented physiological elution conditions (150 mM salt, pH 7 to 8), surpassing the performance of the industry-leading DEAE ligand. Find all our presented posters about Lentivirus vector purification and our synthetic DNA technology at https://www.anjarium.com/ #ASGCT2024 #lentivirus #chromatography #downstreamprocessing #genetherapy #celltherapy #CART #biotech
2 Comments -
Samantha O'Neill
Looking at you UC Davis Genome Center! 💡Investing in automation is an investment into your team! Ultimately an investment in automation is an investment to those you serve! Win-win-win 🥇 And look at how accessible the platform is from any angle 👏🏽 #Automation #Integra #singleCell #ParseBiosciences #UCD #scRNAseq #Genome #Genetics #RNA #WholeTranscriptome
-
MaryAnn Brown
Less than a month and counting . . . The growing demand for recombinant proteins requires simultaneous strategic development, application, and adoption of tools for the efficient expression and production of these valuable biomolecules. The Expression Stream at #PEGSEurope tackles these issues head on. https://lnkd.in/eaVu6nnZ ◼ SHORT COURSE: Tools for Cell Line Engineering and Development – what are the future tools for CLE and CLD? ◼ TRAINING SEMINAR: Current Applications of Host Expression Systems and Optimisation of the CEPA Workflow to Support Therapeutic Generation and Structural Biology – applying CEPA (Cloning, Expression, Purification, Analytics) to your workflow process? ◼ CONFERENCE: Using Data Science to Maximise Protein Production – how are you using data and engineering to evaluate expression hosts? ◼ CONFERENCE: Optimising Expression Platforms - what is the best expression system for producing your recombinant protein of choice? ◼ CONFERENCE: Protein Process Development - what are your throughput goals? These strategic back-to-back meetings investigate the newest data, innovations, and strategies to make the expression of therapeutic proteins more efficient, effective and trouble-free. #biopharmaceuticals #proteinexpression #proteinpurification #Barcelona
2 Comments -
Biotech Networks
SFBN Trending News: Biocytogen and Acepodia Join Forces to Advance Bispecific Antibody and Dual-Payload ADCs for Treating Complex Tumors https://lnkd.in/gn8EHtMm BEIJING & ALAMEDA, Calif. & TAIPEI–(BUSINESS WIRE)–Biocytogen (HKEX: 02315) and Acepodia (6976:TT), today announced a groundbreaking strategic partnership to jointly assess a dual-payload bispecific antibody-drug conjugate (BsAD2C) program. This collaboration combines Biocytogen’s RenLite® platform with [...]
-
May Guo
New IVT method to reduce #dsRNA by covalently tethering RNA polymerase to promoter DNA and attaching the co-complex to magnetic beads. Paper from Professor Craig Martin lab. This new system was tested to synthesize a short RNA, a CRISPR guide RNA, and a protein-coding #mRNA. In all cases, the generation of self-templated double stranded RNA (dsRNA) impurities are greatly reduced. Transfection of the mRNA into HEK293T cells shows a correlation between reduced RNA-templated extensions and significantly increased expression and reduced innate immune stimulation by the mRNA reaction product. Link to paper here: https://lnkd.in/eVVm7jtd
3 Comments -
William Stack
🏷️ Attention Lab Managers, Operations Pros, and Finance Wizards! 🏷️ Our lab equipment auction is in full swing! 🔬🧪 If you haven’t checked it out yet, you’re missing out on serious deals. From high-quality centrifuges to freezers colder than your finance team's budget talks 🥶, we've got premium assets ready for your lab at unbeatable prices! 👉 Why you should jump in: Huge savings on top-notch lab equipment 💰 Exceptional value without compromising quality ⚙️ Assets available now to boost your lab’s efficiency 🔥 Don't wait—gear up your lab, make your finance team proud, and snag those deals while you still can! 🛠️ Visit the auction here https://hubs.la/Q02SkW360 and make sure you grab what you need before it’s gone! #LabEquipment #AuctionDeals #CostSavings #LaboratoryEssentials #SoCalBiotech #SouthernCaliforniaBiotech #CaliBiotech #CaliforniaLifeSciences #SanDiegoBiotech #LAStartups #BioTechLA #OrangeCountyBiotech #SanDiegoLifeSciences
-
Nayoung K. D. Kim
At PROTEINA, our recent publication on bioRxiv demonstrates the groundbreaking capabilities of the Single molecule Protein Interaction Detection (SPID) platform in advancing antibody development with finely-tuned affinities. I’d like to highlight two groundbreaking aspects from this study that are particularly significant: 𝐒𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐜 𝐌𝐨𝐝𝐢𝐟𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬 𝐢𝐧 𝐂𝐃𝐑𝐬: Our targeted edits within the Complementarity Determining Regions (CDRs) of antibodies have led to the discovery of affinity-enhancing mutations. These modifications have successfully produced sub-nanomolar affinity candidates, setting a new benchmark for antibody affinity maturation. 𝐇𝐢𝐠𝐡-𝐭𝐡𝐫𝐨𝐮𝐠𝐡𝐩𝐮𝐭 𝐂𝐡𝐚𝐫𝐚𝐜𝐭𝐞𝐫𝐢𝐳𝐚𝐭𝐢𝐨𝐧: The ability of PROTEINA’s SPID platform to rapidly characterize over 3,000 antibodies weekly is revolutionizing our understanding of antibody-antigen interactions. This capability is crucial for accelerating the development of tailored therapeutic interventions. Almost forgot to mention this! Keep an eye on the future contributions of PROTEINA’s Jihye Jo well!
4 Comments
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore More